Triple

T20263305
Position Surface form Disambiguated ID Type / Status
Subject Air Test and Evaluation Squadron 1 E498899 entity
Predicate abbreviation P43 FINISHED
Object VX-1
VX-1 is a U.S. Navy air test and evaluation squadron responsible for operational testing of maritime patrol, reconnaissance, and other naval aviation systems.
 E1420622 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: VX-1 | Statement: [Air Test and Evaluation Squadron 1, abbreviation, VX-1]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: VX-1
Context triple: [Air Test and Evaluation Squadron 1, abbreviation, VX-1]
  • A. VX-31
    VX-31 is a United States Navy air test and evaluation squadron responsible for testing and assessing the performance of naval aircraft and related systems.
  • B. VX-21
    VX-21 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft, weapons, and related systems.
  • C. VX-24
    VX-24 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft systems and weapons.
  • D. VX-548
    VX-548 is an investigational non-opioid pain medication developed by Vertex Pharmaceuticals that targets NaV1.8 sodium channels to treat acute and chronic pain.
  • E. VX-880
    VX-880 is an investigational cell-based therapy being developed by Vertex Pharmaceuticals for the treatment of type 1 diabetes by replacing lost insulin-producing beta cells.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: VX-1
Triple: [Air Test and Evaluation Squadron 1, abbreviation, VX-1]
Generated description
VX-1 is a U.S. Navy air test and evaluation squadron responsible for operational testing of maritime patrol, reconnaissance, and other naval aviation systems.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: VX-1
Target entity description: VX-1 is a U.S. Navy air test and evaluation squadron responsible for operational testing of maritime patrol, reconnaissance, and other naval aviation systems.
  • A. VX-31
    VX-31 is a United States Navy air test and evaluation squadron responsible for testing and assessing the performance of naval aircraft and related systems.
  • B. VX-21
    VX-21 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft, weapons, and related systems.
  • C. VX-24
    VX-24 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft systems and weapons.
  • D. VX-548
    VX-548 is an investigational non-opioid pain medication developed by Vertex Pharmaceuticals that targets NaV1.8 sodium channels to treat acute and chronic pain.
  • E. VX-880
    VX-880 is an investigational cell-based therapy being developed by Vertex Pharmaceuticals for the treatment of type 1 diabetes by replacing lost insulin-producing beta cells.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69da6275fa6c8190952924930adee150 completed April 11, 2026, 3:02 p.m.
NER Named-entity recognition batch_69e674ccff008190920b418f51dc4311 completed April 20, 2026, 6:47 p.m.
NED1 Entity disambiguation (via context triple) batch_6a0855311d4c8190bab2119e20359ae9 completed May 16, 2026, 11:29 a.m.
NEDg Description generation batch_6a0855c6bab08190831cc78647de84fc completed May 16, 2026, 11:32 a.m.
NED2 Entity disambiguation (via description) batch_6a0856e66c808190b5ef994f1cbc5f3e completed May 16, 2026, 11:37 a.m.
Created at: April 11, 2026, 11:41 p.m.